Immunotherapy in Non-small Cell Lung Cancer Treatment
DOI:
https://doi.org/10.58445/rars.1174Keywords:
Immunotherapy, Non-small Cell Lung Cancer, CancerAbstract
Cancer is the uncontrolled development of cells, a class of diseases that poses a health threat worldwide. The immune system serve as a formidable defense mechanism against illnesses, infections, and other diseases. Cancer can undermine the immune system. Therefore, immunotherapy emerges as a promising solution that utilize the immune system to combat cancer and overcome cancer immune evasion. Non-small Cell Lung Cancer (NSCLC) is the most prevalent and lethal form of lung cancer. A type of immunotherapy, Immune Checkpoint Inhibitors (ICI) is used to cure NSCLC and is introduced as a first line treatment option. Despite the improved survival rates for ICI, it is crucial to acknowledge the immune-related adverse events and side effects that persist when being treated. This review provides a thorough overview of NSCLC, its treatment, innovation,ongoing clinical trials and prospects. Current medical research has highlight the evolving landscape of immunotherapy in NSCLC treatment. To ensure more effective treatment outcome and accessability, it is important to have more study and research being conducted to discover individualized and combination treatments.
References
Baiu, I., Titan, A. L., Martin, L. W., Wolf, A., & Backhus, L. (2021). The role of gender in non-small cell lung cancer: a narrative review. Journal of thoracic disease, 13(6), 3816
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018). Cell death-based treatment of lung adenocarcinoma. Cell death & disease, 9(2), 117. https://doi.org/10.1038/s41419-017-0063-y
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019). Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(15), 4592–4602. https://doi.org/10.1158/1078-0432.CCR-18-1538
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., ... & Yang, S. C. (2010). Non–small cell lung cancer. Journal of the national comprehensive cancer network, 8(7), 740-801.
Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G., & Tran, A. (2018). Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of immunology research, 2018, 9585614. https://doi.org/10.1155/2018/9585614
Mithoowani, H., & Febbraro, M. (2022). Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current oncology (Toronto, Ont.), 29(3), 1828–1839. https://doi.org/10.3390/curroncol29030150
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020). Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. Journal of Clinical Medicine, 9(5), 1362. https://doi.org/10.3390/jcm9051362
Paz-Ares, L. G., Ramalingam, S. S., Ciuleanu, T. E., Lee, J. S., Urban, L., Caro, R. B., Park, K., Sakai, H., Ohe, Y., Nishio, M., Audigier-Valette, C., Burgers, J. A., Pluzanski, A., Sangha, R., Gallardo, C., Takeda, M., Linardou, H., Lupinacci, L., Lee, K. H., Caserta, C., … Reck, M. (2022). First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(2), 289–308. https://doi.org/10.1016/j.jtho.2021.09.010
Putzu, C., Canova, S., Paliogiannis, P., Lobrano, R., Sala, L., Cortinovis, D. L., & Colonese, F. (2023). Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment? Cancers, 15(3), 689. https://doi.org/10.3390/cancers15030689
Qin, A., Coffey, D. G., Warren, E. H. (2016). Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Medicine, 5(9), 2567-2578. https://doi.org/10.1002/cam4.819
“The Immune System and Cancer.” Cancer Research UK, 6 Nov. 2023, www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-immune-system-and-cancer#:~:text=Cancer%20can%20weaken%20the%20immune%20system%20by%20spreading%20into%20the,making%20so%20many%20blood%20cells.
“What Is Cancer?” National Cancer Institute, 2021, www.cancer.gov/about-cancer/understanding/what-is-cancer.
Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: current treatment and future advances. Translational lung cancer research, 5(3), 288–300. https://doi.org/10.21037/tlcr.2016.06.07
Downloads
Posted
Categories
License
Copyright (c) 2024 Yee Lut Aniece Wong, Ashley Pearson
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.